<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03205488</url>
  </required_header>
  <id_info>
    <org_study_id>NILO-PD</org_study_id>
    <nct_id>NCT03205488</nct_id>
  </id_info>
  <brief_title>Nilotinib in Parkinson's Disease</brief_title>
  <acronym>NILO-PD</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and tolerability of daily oral administration of nilotinib
      (150-300mg once daily) in Parkinson's Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine if nilotinib is safe, if it can be tolerated by
      patients with Parkinson's disease (PD) and to learn if nilotinib has the possibility of
      effectively treating PD symptoms. Nilotinib has been approved by the Food and Drug
      Administration (FDA) to treat certain types of cancer (leukemia) but is considered
      investigational in this study because it has not been approved for treating PD. Twenty-five
      sites will enroll participants into 2 cohorts,approximately 75 in Cohort 1 and 60 in Cohort
      2. Participants with moderate to advanced PD symptoms will be enrolled in Cohort 1, randomly
      assigned to take nilotinib (150 mg or 300mg) or placebo, and will complete 13 in-person study
      visits over 8.5 months.

      The results from Cohort 1 will determine if either dose of nilotinib (150mg or 300 mg) is
      safe and tolerable enough to move forward and evaluate in Cohort 2. If either dose is found
      to be safe and tolerable, participants with early PD will be enrolled into Cohort 2.

      Participants in Cohort 2 will be randomly assigned to either nilotinib (dose to be determined
      from Cohort 1 results) or placebo and will complete 17 in-person visits over 14.5 months. For
      both cohorts, the study visits will include clinical assessment of motor, neuropsychiatric
      and cognitive testing as well as collection of blood and cerebral spinal fluid, collected by
      lumbar puncture.

      This study will also evaluate if nilotinib can help improve motor symptoms associated with
      PD. All participants in Cohort 1 and participants in Cohort 2 who have started PD medications
      will have an assessment of the motor exam (Part III) in a practically defined OFF state (12
      hours post dose) and ON state (at least one-hour post dose).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Cohort 1 = 6 months, Cohort 2 = 12 months</time_frame>
    <description>the frequency of treatment-related serious adverse events across all groups within each cohort</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Cohort 1 = 6 months, Cohort 2 = 12 months</time_frame>
    <description>The ability to complete the study on the assigned dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Motor Function</measure>
    <time_frame>6 months</time_frame>
    <description>Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (motor function) will be evaluated to determine if Nilotinib has the potential to reduce the MDS-UPDRS motor score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moderate to Advanced PD Population Randomized 1:1:1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Early/de novo Randomized 2:1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)</intervention_name>
    <description>2 capsules taken once daily</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)</intervention_name>
    <description>2 capsules taken once daily</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 capsules taken once daily</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria; Cohort 1 and 2:

          1. Idiopathic PD based on the UK Brain Bank diagnostic criteria.

          2. Any race and either gender, age 40-79

          3. Able to read and understand English with the capacity to provide voluntary informed
             consent by signing the informed consent form (ICF)

          4. Willing to comply with all study procedures including multiple multiple lumbar
             punctures (LP)

          5. Must be on a stable regimen of central nervous system acting medications (if
             applicable) for at least 30 days prior to the baseline visit (e.g., benzodiazepines,
             antidepressants, hypnotics)

        Inclusion criteria specific for Cohort 1:

        6a. Diagnosis of PD duration &gt; 5 year

        7a. Hoehn &amp; Yahr scale (H&amp;Y) stage &gt; 2 and &lt; 4 in the ON state

        8a. Must be on a stable regimen of PD medications, that includes levodopa, for at least 30
        days prior to the screening visit A. Treatment with monoamine oxidase B (MAO-B) inhibitors
        will be allowed provided the dose has been stable for 60 days prior to baseline

        Inclusion criteria specific for Cohort 2:

        6b. Diagnosis of PD duration &lt; 3 years

        7b. H&amp;Y stage ≤ 2 8b. Participants who are currently NOT receiving symptomatic therapy (ST)
        (levodopa,dopamine agonists and monoamine oxidase B (MAO-B) inhibitors) and NOT projected
        to require ST for at least 3 months from enrollment.

        a. Treatment with amantadine or an anticholinergic agent will be allowed provided the dose
        has been stable for 30 days prior to screening and will remain stable for the duration of
        the study

        Exclusion Criteria; Cohorts 1 and 2:

          1. Diagnosis of atypical parkinsonism

          2. History of bipolar disorder or major depression, or presence of active depression
             defined as a Beck Depression Inventory II (BDI-II) score &gt;17

          3. History of a suicide attempt within the last 5 years or active suicidal ideations

          4. History of schizophrenia or schizophrenia spectrum disorders

          5. History of uncontrolled hypokalemia or hypomagnesaemia, or laboratory evidence of such
             on screening

          6. History of cardiac arrhythmia, long QT syndrome, or a corrected QT interval (QTcF)
             ≥450ms at screening visit 1

          7. Treated within 30 days prior to randomization, or planned use during the trial with
             any of the following classes of Concomitant drugs:

               1. Class IA or III antiarrhythmic drugs

               2. QT prolonging drugs

               3. Strong CYP3A4 inhibitors or inducers

               4. Anticoagulants

               5. Proton pump inhibitors

          8. A clinical history, or the active presence of a cardiovascular condition including:

               1. Myocardial infarction, known cardiac ischemia, or angina

               2. Cerebrovascular event (e.g. embolic stroke)

               3. Congestive heart failure, symptomatic first degree atrioventricular (AV) block or
                  PR interval &gt; 220msec and all second and third degree AV block, second- or
                  third-degree atrioventricular block, sick sinus syndrome, or other serious
                  cardiac rhythm disturbances

               4. History of Torsade de Pointes

               5. Other cardiovascular history that, in the opinion of the Site Investigator, will
                  preclude study participation

          9. History of hepatic disease, including abnormal liver function defined as Total
             Bilirubin &gt; 1.5 times upper limit, Aspartate Aminotransferase (AST) and/or Alanine
             Aminotransferase (ALT) &gt; 2 times the upper limit of the normal, or coagulopathy with
             INR &gt; 1.4

         10. History of epilepsy or a seizure within the last 6 months

         11. Active malignancy, or history of a neoplasm in the prior 5 years (excluding
             basal/squamous cell carcinoma)

         12. Prior history of pancreatitis or total gastrectomy or evidence of abnormal pancreatic
             function defined as elevated amylase and/or lipase &gt; 2 times upper limit of normal

         13. Diagnosis of human immunodeficiency virus (HIV), clinically significant chronic
             hepatitis such as hepatitis B (HBV) or hepatitis C (HCV), or clinical history or signs
             of an active infection

         14. History of drug or alcohol abuse ≤ 5 years

         15. Active medical or psychiatric condition that in the opinion of the Site Investigator
             should preclude study participation

         16. Previous surgical management for PD

         17. Participants participating in any drug or device clinical investigation concurrently
             or within 30 days prior to screening for this study

         18. Severe lactose and galactose intolerance

         19. Participants with evidence of other significant laboratory abnormalities which in the
             opinion of the site investigator or clinical monitor should preclude study
             participation

         20. Known hypersensitivity or contraindication to study drugs (nilotinib or matching
             placebo) or their components.

         21. Female participants of child-bearing potential. Female participants must be
             post-menopausal, post-hysterectomy, or have a documented infertility based on a known
             medical or surgical condition

         22. Participants with a history of bone marrow suppression or evidence of persistent
             myelosuppression defined as absolute neutrophil count &lt;1.8 X 109/L, significant
             anemia, or thrombocytopenia defined as platelet count &lt; 100 X 109/L

        Exclusion criteria specific for Cohort 1:

        22a. Diagnosis of dementia based on the clinician's assessment, or a Montreal Cognitive
        Assessment (MoCA) score &lt; 21 at baseline

        Exclusion criteria specific for Cohort 2:

        22b.MoCA score &lt; 26 at baseline

        23b. Treated within 60 days prior to randomization or expected to require treatment within
        3 months from randomization with any ST (including levodopa and dopamine agonists )

        a. Treatment with amantadine or an anticholinergic agent will be allowed provided the dose
        has been stable for 30 days prior to screening and will remain stable for the duration of
        the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanya Simuni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tina Ward, MS</last_name>
    <phone>877-483-1834</phone>
    <email>NILO_STUDY@chet.rochester.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Richardson</last_name>
      <phone>205-934-0074</phone>
      <email>jhrichardson@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Natividad Stover, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Harrigan</last_name>
      <phone>602-406-3343</phone>
      <email>mary.harrigan@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Holly Shill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado at Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Hosford</last_name>
      <phone>303-724-6247</phone>
      <email>lindsay.hosford@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Lauren Seeberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Ridgeway</last_name>
      <phone>352-273-9194</phone>
      <email>derek.ridgeway@neurology.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Camille Swartz</last_name>
      <phone>352-273-5612</phone>
      <email>cami.swartz@neurology.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adolfo Ramirez-Zamora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Rocha</last_name>
      <phone>813-396-0757</phone>
      <email>crocha1@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Hauser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Kelly</last_name>
      <phone>312-942-7054</phone>
      <email>brian_j_kelly@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Gian Pal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0284</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Wagner</last_name>
      <phone>859-323-0028</phone>
      <email>renee.wagner@uky.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michael Nsoesie</last_name>
      <phone>859-323-5178</phone>
      <email>michael.nsoesie@uky.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Slevin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine Yoritomo</last_name>
      <phone>410-616-2822</phone>
      <email>nyorito1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Liana Rosenthal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Bwala</last_name>
      <phone>617-643-0654</phone>
      <email>gbwala@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Albert Hung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Stovall</last_name>
      <phone>734-647-4787</phone>
      <email>astovall@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Kelvin Chou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doozie Russell</last_name>
      <phone>517-884-2274</phone>
      <email>doozie.russell@hc.msu.edu</email>
    </contact>
    <investigator>
      <last_name>John Goudreau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic - Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hooman Homar</last_name>
      <phone>702-462-6804</phone>
      <email>honarh@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Milagros Formoso</last_name>
      <phone>702-331-7049</phone>
      <email>formosm@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Zoltan Mari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Ramirez</last_name>
      <phone>212-844-6571</phone>
      <email>laura.ramirez@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Susan Bressman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Ratel</last_name>
      <phone>212-305-3938</phone>
      <email>ads2178@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Oren Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Gauger</last_name>
      <phone>919-668-1538</phone>
      <email>lisa.gauger@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Burton Scott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Neefus</last_name>
      <phone>513-558-6555</phone>
      <email>neefusem@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Duker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvette Pitchford</last_name>
      <phone>216-444-7513</phone>
      <email>ellisy@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Anwar Ahmed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandon Labadie</last_name>
      <phone>503-494-7275</phone>
      <email>labadie@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kellie Keith</last_name>
      <phone>503-494-9531</phone>
      <email>keithk@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kathryn Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Deck</last_name>
      <phone>215-829-7128</phone>
      <email>benjamin.deck@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Meredith Spindler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shonna Jenkins</last_name>
      <phone>843-792-9115</phone>
      <email>jenkisho@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Vanessa Hinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Fleetwood</last_name>
      <phone>901-448-7375</phone>
      <email>emesseng@vols.utk.edu</email>
    </contact>
    <investigator>
      <last_name>Mark LeDoux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ami Patel</last_name>
      <phone>713-798-6902</phone>
      <email>ami.patel@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Joohi Jimenez-Shahed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Sullivan</last_name>
      <phone>434-982-6599</phone>
      <email>kls8d@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kara Thornton</last_name>
      <phone>434-982-1048</phone>
      <email>krp4h@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Binit Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Neurological</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Bixby</last_name>
      <phone>509-960-2818</phone>
      <email>mbixby@inwresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jason Aldred, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Wheeler</last_name>
      <phone>414-805-9307</phone>
      <email>lwheeler@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marie Mejaki</last_name>
      <phone>414-805-5287</phone>
      <email>mmejaki@mcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Karen Blindauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Northwestern</keyword>
  <keyword>Nilotinib</keyword>
  <keyword>USA</keyword>
  <keyword>NILO-PD</keyword>
  <keyword>Parkinson Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

